- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02285023
The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL)
Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL)
Study Overview
Detailed Description
- Adaption of the Cu-Q2oL questionnaire into Thai version by using forward-backward translation that is independently performed by two bilingual translators. The original Italian version is translated into Thai by two Thai native speakers, then the study team reviews the Thai-version Cu-Q2oL questionnaire for items comprehensibility and integrates the first consensus version which re-translated into Italian by an Italian native speaker afterwards. The comparison between the backward Italian version Cu-Q2oL questionnaire and the original Cu-Q2oL is carried out to find out whether there are any misconception and mistranslation in the intermediary forward version of questionnaire. After that, the second consensus version will be tested on 15 chronic urticaria patients to detect any misunderstanding points based on patients' comments. Finally, this Thai-version of CU-Q2oL questionnaire will be used to investigate the validity, reliability, interpretability and minimal clinical important difference.
- To investigate the validity, reliability and interpretability of Thai-version of Chronic Urticaria Quality of Life Questionaire (CU-Q2oL), the severity of chronic urticaria symptoms will be assessed by investigators and patients using the Urticaria Activity Score (UAS7), the DLQI and CU-Q2oL questionnaire.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10700
- Siriraj Hospital, Mahidol University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18 years old or above
- Diagnosed as chronic urticaria based on "The EAACI/GA(2)LEN/EDF/WAO Guideline
- Literate in Thai language and can complete the questionnaire by themselves
Exclusion Criteria:
- Have other active skin diseases
- Have a psychiatric problem
- Cannot understand the questionnaire by themselves.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CU-Q2oL
|
The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home. At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up. At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cross-Cultural Validity of Thai-version CU-Q2oL
Time Frame: 4 week
|
Cross-cultural validity is the degree to which the performance of the Thai CU-Q2oL items can adequately reflect the performance of the original CU-Q2oL items.
Exploratory factor analysis was used to determine scales with proper item division of the Thai CU-Q2oL.
Principal component analysis with varimax rotation was employed.
An eigenvalue ≥ 1 was chosen as the criterion to retain domains.
Each item was classified into the domain when loading with a domain loading ≥ 0.5.
|
4 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Total Score and Domain of Thai CU-Q2oL Scores From the Thai Version to Investigate Reliability of Thai-Version CU-Q2oL
Time Frame: baseline
|
- The CU-Q2oL Questionnaire is a 23-item HRQoL questionnaire. It measures three dimensions (scales) of HRQoL: domain I (sleep, leisure, concentration), domain II (symptom, eating limits), and domain III (mental status, looks, impact on life activities) The scores of domain I of CUQ2oL range between 0 and 26. The scores of domain II of CUQ2oL range between 0 and 39.The scores of domain III of CUQ2oL between 0 and 35. The minimum possible score is 0 and the maximum possible score is 100 for total scale. -The DLQI scores range from 0-30. Domain I (leisure), Domain II (symptoms and feeling), and Domain III (daily activities, work, school, and personal relationships). Meaning of DLQI Scores: 0-1 = no effect, 2-5 = small effect, 6-10 = moderate effect, 11-20 = very large effect, 21-30 = extremely large effect. The higher the score, the more quality of life is impaired for both the CUQ2oL and the DLQI. |
baseline
|
Change in Thai CU-Q2oL Scores From Baseline for Responders and Non-Responders
Time Frame: baseline and 2 weeks
|
- Investigate the smallest reduction in the Thai CU-Q2oL that patients recognized as a meaningful improvement.
|
baseline and 2 weeks
|
Area Under the Curve for Thai CUQ2oL Scores in the Responder Group
Time Frame: baseline and 2 weeks
|
The receiver operating characteristic (ROC) analysis and area under the curve (AUC) are acceptable as the units of measure for assess the ability of a questionnaire to changes in patients' health-related quality of life (HRQoL) impairment over time that represents to responsiveness to change and minimal clinical important difference (MCID). The AUC of the ROC analysis of 1, 0.9, 0.8, 0.7 and 0.5 were considered perfect, excellent, good, fair, and no better than chance, respectively. |
baseline and 2 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kanokwalai Kulthanan, MD, Mahidol University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Thai-version of CU-Q2oL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Urticaria
-
Marcus MaurerCompletedNon-autoreactive Chronic Spontaneous Urticaria | Autoimmune Chronic Spontaneous Urticaria | Autoreactive, Non-autoimmune Chronic Spontaneous UrticariaGermany
-
United BioPharmaCompleted
-
University Hospital, LilleRecruitingSpontaneous Urticaria, ChronicFrance
-
United BioPharmaNot yet recruiting
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedUrticaria ChronicUnited States
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
University Hospital Inselspital, BerneNovartis; University of Bern; Adverse Drug Reactions, Advice and Consulting ADR-ACCompletedChronic Idiopathic Urticaria | Chronic Urticaria | Chronic Spontaneous UrticariaSwitzerland
-
J. Uriach and CompanyTerminated
-
Simon Francis ThomsenAarhus University HospitalRecruitingChronic Spontaneous Urticaria | Chronic Urticaria, IdiopathicDenmark
-
Yuhan CorporationRecruitingAllergic Disease | Chronic Spontaneous Urticaria | Cold Urticaria | Chronic Inducible UrticariaKorea, Republic of
Clinical Trials on CU-Q2oL
-
Cutia Therapeutics(Wuxi)Co.,LtdCompleted
-
Clarity Pharmaceuticals LtdCompleted
-
Enrico M NovelliNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rigshospitalet, DenmarkRecruitingBorrelia Burgdorferi NeuroborreliosisDenmark
-
Ralph Weissleder, MDRecruitingCardiovascular Diseases | Cancer | SarcoidUnited States
-
Cutia Therapeutics(Wuxi)Co.,LtdRecruiting
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Recruiting
-
Collaborative Medicinal Development Pty LimitedUnknown
-
Washington University School of MedicineCompletedCarotid AtherosclerosisUnited States
-
Sohag UniversityActive, not recruitingIUD; Complications, Infection or Inflammation | IUD (Intrauterine Device) MalpositionEgypt